Cheng Li

Dr. Cheng “Cynthia” Li serves as Vice President of Business and Corporate Development at Spotlight Therapeutics. She brings over 10 years of oncology research, pharma, and biotech experience, with core expertise in business development and commercial strategy and planning. Just prior to joining Spotlight, Dr. Li served as Senior Director, Business Development at Exelixis, where she led global search & evaluation efforts and was responsible for closing multiple licensing agreements to build an innovative oncology pipeline with both small molecules and biologics therapeutics behind Exelixis’ flagship product Cabometyx (cabozantinib). Prior to her business development role, Dr. Li was Director of Market Planning, part of the commercial organization and Cabometyx launch team, where she helped build out primary market research, competitive intelligence, and pipeline and business development analytics capabilities. Prior to Exelixis, Dr. Li held roles of increasing responsibility for business analytics within the Kyprolis (carfilzomib) commercial and US launch team at Onyx and Amgen.

Dr. Li received her B.S. in Biotechnology from Huazhong University of Science and Technology and Ph.D. in Molecular Cell Biology from Washington University in St. Louis.